中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
22期
1408-1411
,共4页
贾晓青(综述)%柳光宇(审校)
賈曉青(綜述)%柳光宇(審校)
가효청(종술)%류광우(심교)
乳腺癌%内分泌耐药%依维莫司%mTOR抑制剂%坦罗莫司
乳腺癌%內分泌耐藥%依維莫司%mTOR抑製劑%坦囉莫司
유선암%내분비내약%의유막사%mTOR억제제%탄라막사
breast cancer%endocrine resistance%everolimus%mTOR inhibitor%temsirolimus
靶向激素受体（hormone receptor，HR）和人类表皮生长因子（human epidermal growth factor receptor 2，HER-2）对激素受体阳性乳腺癌的治疗至关重要，然而原发或继发内分泌治疗耐药及后续的疾病进展仍不可避免。人哺乳动物雷帕霉素位点（mammalian target of rapamycin，mTOR）是细胞生长和分化的关键调节因子，参与细胞不可控性生长。目前许多研究表明mTOR通路的激活可能与乳腺癌内分泌治疗耐药相关，阻断此通路有助于消除耐药，维持药物的敏感性。许多靶向mTOR通路的药物均表现出强大的抗肿瘤效应，在乳腺癌治疗中具有良好前景，且已有许多临床试验结果表明mTOR抑制剂联合内分泌治疗可显著提高患者的生存率。本文对mTOR信号通路及其抑制剂在内分泌治疗耐药的乳腺癌中的新进展进行综述。
靶嚮激素受體（hormone receptor，HR）和人類錶皮生長因子（human epidermal growth factor receptor 2，HER-2）對激素受體暘性乳腺癌的治療至關重要，然而原髮或繼髮內分泌治療耐藥及後續的疾病進展仍不可避免。人哺乳動物雷帕黴素位點（mammalian target of rapamycin，mTOR）是細胞生長和分化的關鍵調節因子，參與細胞不可控性生長。目前許多研究錶明mTOR通路的激活可能與乳腺癌內分泌治療耐藥相關，阻斷此通路有助于消除耐藥，維持藥物的敏感性。許多靶嚮mTOR通路的藥物均錶現齣彊大的抗腫瘤效應，在乳腺癌治療中具有良好前景，且已有許多臨床試驗結果錶明mTOR抑製劑聯閤內分泌治療可顯著提高患者的生存率。本文對mTOR信號通路及其抑製劑在內分泌治療耐藥的乳腺癌中的新進展進行綜述。
파향격소수체（hormone receptor，HR）화인류표피생장인자（human epidermal growth factor receptor 2，HER-2）대격소수체양성유선암적치료지관중요，연이원발혹계발내분비치료내약급후속적질병진전잉불가피면。인포유동물뢰파매소위점（mammalian target of rapamycin，mTOR）시세포생장화분화적관건조절인자，삼여세포불가공성생장。목전허다연구표명mTOR통로적격활가능여유선암내분비치료내약상관，조단차통로유조우소제내약，유지약물적민감성。허다파향mTOR통로적약물균표현출강대적항종류효응，재유선암치료중구유량호전경，차이유허다림상시험결과표명mTOR억제제연합내분비치료가현저제고환자적생존솔。본문대mTOR신호통로급기억제제재내분비치료내약적유선암중적신진전진행종술。
Therapies targeting endocrine receptors and human epidermal growth factor receptor 2 have become important treat-ment modes for patients with hormone receptor breast cancer. Despite the availability of these options, however, development of prima-ry or secondary drug resistance and subsequent disease progression in patients with advanced disease continue to occur. Mammalian tar-get of rapamycin (mTOR), a key regulator of cell growth and proliferation, has been implicated in the induction of cellular processes leading to the uncontrolled growth of cancer cells. Recent studies have suggested that overactivation of the mTOR pathway may be in-volved in the development of endocrine resistance. Interrupting this signaling cascade may alleviate such resistance and help restore drug sensitivity. A number of agents targeting the mTOR pathway have shown potent anti-tumorigenic effects in vitro, and several agents show great potential for treating breast cancer patients. Many clinical studies have shown that combining endocrine therapy with mTOR inhibitors could significantly increase the survival rate of breast cancer patients. In this study, we focus on recent research prog-ress on mTOR and its inhibitors in endocrine therapy resistance in breast cancer.
